The results presented here represent the best that have ever been published by a UK vision correction provider. The evidence for this is as follows:
On their website, Accuvision present information with regard to myopic outcomes, restricted to astigmatism going up to a maximum of -2.00DC and under 8 dioptres of myopia. This is data from individual eye treatments, but the website does not state that it is independently verified, nor does it specify if it is stratified in terms of the more rigorous mean spherical equivalent rather than sphere value alone. The Accuvision results are impressive in that they present a weighted mean of some 97% 6/6 vision overall.
The weighted mean of the Ultralase sample, stratified by the exacting post-operative MSE criterion is also 97% but involves astigmatic corrections of up to -5.5 DC in the table. Therefore, by equalling the overall weighted mean with a wider ranging sample, even without any independent verification this sample is superior to the Accuvision study.
Optimax state in their advertising that they offer “the same treatment and the same results at half the cost”. They state results (not independently verified) of 99.5% corrected to 6/12 unaided, 89.1% corrected to 6/6 unaided, and 91.5% within ±0.50 postop MSE unaided.
Not only does their equipment fall short in terms of safety safeguards like real-time Iris Recognition tracking but it lacks technological advantages like asphericity compensation, meaning that it is not the “same treatment for the same price”. Also, their results fall short of those declared in this document. Ultralase Ultra Elite treatment is now shown to correct 99.6% to 6/12, 95.8% to 6/6 and 95.4% to ±0.50.
OE have produced published results as a paid supplement to the July 2009 Journal of Refractive Surgery. These have a 77% accountability but are declared as being verified by a data management corporation in Kentucky, USA. They state 92% of myopic eyes with a similar range of sphere but with unclear astigmatic error achieve 6/6 and 94% of eyes achieve a residual post-operative prescription of ±0.50 MSE.
Ultralase Ultra Elite treatment is now shown to correct 99.6% to 6/12, 95.8% to 6/6 and 95.4% to ±0.50.
LONDON VISION CLINIC
The results of 1200 eyes which are declared on the LVC website are of a high standard. They state 100% of patients achieve 6/12 and 98% achieve 6/6, which on the face of it would appear to exceed those of Ultralase. However, this is not an identical comparison of like-with-like to make as the LVC results are only declared at discharge, and for some of the eyes this is after a retreatment. The Ultralase sample is exclusively the results of primary treatments, and therefore no fair parallel can be made between Ultralase results and those of the LVC.
ADVANCE VISION CARE
A sample of 1200 eyes is declared with 91% achieving 6/6 vision and 91% achieving within ±0.50 MSE.
Ultralase Ultra Elite treatment corrects 95.8% to 6/6 and 95.4% to ±0.50.
No table of results declared
No table of results declared, those stated on the website of the company are FDA results for their laser but not their surgeons in their clinics.
Not only do the Ultralase results exceed those of Focus, but they are those of Ultralase patients treated by Ultralase surgeons in Ultralase clinics
CENTRE FOR SIGHT
Centre for Sight declare a 98% 6/6 figure for Intralase LASIk for the correction of myopia but writted in small letters at the bottom of the graph they state that this is Best Corrected Spectacle Visual Acuity and not Uncorrected Distance Visual Acuity, as Ultralase’s results are. Therefore, these results are not able to be compared with those of Ultralase.
The Ultralase Ultra Elite results given here represent the best set of laser vision correction of results ever published by a UK clinic group.